Asmin 2mg Tablet

Asmin 2mg Tablet contains Montelukast 2mg, a lower, non-standard strength of this leukotriene receptor antagonist within the Asmin brand family, generally understood to be intended for very young children who have been diagnosed with asthma-related wheezing or, in some cases, allergic rhinitis. As with all montelukast-based medicines, it works by blocking leukotrienes, chemicals in the body that contribute to airway inflammation, narrowing, and mucus production, helping to reduce the frequency of breathing difficulties in children who are too young for the standard 4mg or 5mg strengths.

Because this 2mg strength is less commonly documented than the standard paediatric strengths, the exact age range it is intended for should always be confirmed directly with the prescribing doctor rather than assumed. Asmin 2mg Tablet is a prescription-only medicine in Malaysia, and DoctorOnCall requires an online medical consultation so a doctor can confirm the child’s diagnosis, age, and weight-appropriate strength before a prescription is issued and the medicine is dispensed by a registered pharmacist.

Montelukast selectively blocks the cysteinyl leukotriene receptor (CysLT1) on airway tissue, preventing leukotrienes from triggering inflammation, swelling, and constriction of the small airways. In very young children, this lower 2mg strength is intended to provide the same preventive mechanism at a dose considered appropriate for their smaller body size, though exact dosing should always be confirmed with the prescribing doctor given the less standardised nature of this strength.

Asmin 2mg Tablet should be given exactly as instructed by the child’s doctor, typically once daily in the evening, and the pharmacist’s specific instructions on how to prepare or administer the tablet to a very young child should be followed closely. Given the non-standard nature of this strength, caregivers should confirm the exact administration method (such as whether it may be dispersed in a small amount of liquid) with the dispensing pharmacist before first use.

The dosing of Asmin 2mg Tablet should be set individually by the prescribing doctor for the specific young child, taking into account age, weight, and the severity of symptoms; because 2mg is a lower and less standard strength, parents should not assume dosing frequency based on other montelukast products and should rely only on the doctor’s explicit instructions. This medicine does not relieve a sudden asthma attack, so any rescue treatment prescribed separately should still be kept on hand.

Asmin 2mg Tablet should be used within the shelf life printed on the packaging when stored correctly. Do not use the tablets after the expiry date shown on the box, and any unused or expired medicine should be disposed of safely.

Store Asmin 2mg Tablet at room temperature, away from direct light, heat, and moisture, in its original packaging until the next dose is due. Keep the medicine well out of the reach of children, taking particular care given that this product is intended for very young children who may be curious about small tablets.

• Known hypersensitivity to montelukast or any ingredient in the tablet
• Not intended for relief of acute asthma attacks or status asthmaticus
• Use with particular caution and only under a doctor’s explicit guidance in very young children, given the limited standardisation of this specific 2mg strength
• Should not replace other prescribed asthma medicines without the doctor’s specific instruction
• Use only under medical guidance if the child has liver impairment

• May interact with certain enzyme-inducing medicines such as phenobarbital or rifampicin, which can reduce montelukast’s effect
• Inform the doctor of all other medicines, including other asthma or allergy treatments, the child is taking
• No significant food restrictions are established, and it should be given as specifically directed by the doctor or pharmacist
• Do not combine with other leukotriene modifiers unless specifically directed by the doctor

• Confirm the exact age suitability and dosing schedule with the prescribing doctor before starting, as this is a lower, less standard strength
• Give the dose at the same time each day to build a consistent routine
• Do not adjust the dose based on assumptions from other montelukast products
• Watch closely for any new or unusual symptoms in very young children and report them promptly
• Keep all scheduled follow-up appointments so the doctor can review the child’s response to treatment
• Store safely and well out of reach given the very young intended age group

Asmin 2mg Tablet represents a lower-strength option within the Asmin brand family, and because this specific strength is less widely documented than the standard 4mg and 5mg montelukast products, parents and caregivers are strongly encouraged to confirm the exact indicated age range and dosing directly with the prescribing doctor or pharmacist rather than relying on general assumptions. Any change in the child’s symptoms, or lack of expected improvement, should be discussed at follow-up so the doctor can reassess the treatment plan.